To evaluate anti-tumor activity in this model, CD8+ CAR T cells were infused in tumor-bearing NSG mice 10 days after s.c. injection of A549 cells and tumor growth was followed for 1 month (see scheme in Fig. 7F). Here, CD8A is linked to neoplasm.